Gland Pharma Limited — Board Meeting, 04-11-2024: Outcome of Board Meeting

Gland Pharma Limited reported its Q2 FY25 financial performance, showing a 2% year-over-year revenue increase to ₹14,058 million, with an EBITDA of ₹2,961 million. The company saw a 12% quarter-over-quarter EBITDA rise but an 8% annual decline. A new director, Ms. Wei Huang, was appointed. The board also restructured its committees. Despite a challenging environment, Gland's core business remains strong, maintaining a 34% EBITDA margin. The company emphasized ongoing strategic growth initiatives in various markets.